Last reviewed · How we verify
SOC: Soluble guanylate cyclase stimulator
Soluble guanylate cyclase stimulators directly activate the enzyme soluble guanylate cyclase to increase intracellular cyclic GMP levels, promoting vasodilation and reducing pulmonary vascular resistance.
Soluble guanylate cyclase stimulators directly activate the enzyme soluble guanylate cyclase to increase intracellular cyclic GMP levels, promoting vasodilation and reducing pulmonary vascular resistance. Used for Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension.
At a glance
| Generic name | SOC: Soluble guanylate cyclase stimulator |
|---|---|
| Sponsor | Actelion |
| Drug class | Soluble guanylate cyclase stimulator |
| Target | Soluble guanylate cyclase (sGC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Soluble guanylate cyclase (sGC) is an intracellular enzyme that produces cyclic GMP (cGMP), a key signaling molecule in vascular smooth muscle relaxation. By directly stimulating sGC independent of nitric oxide availability, these drugs increase cGMP production, leading to smooth muscle relaxation, vasodilation, and improved hemodynamics. This mechanism is particularly beneficial in pulmonary hypertension where endothelial dysfunction impairs the nitric oxide-cGMP pathway.
Approved indications
- Pulmonary arterial hypertension
- Chronic thromboembolic pulmonary hypertension
Common side effects
- Headache
- Dizziness
- Dyspepsia
- Hypotension
Key clinical trials
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension (PHASE3)
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PHASE2)
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOC: Soluble guanylate cyclase stimulator CI brief — competitive landscape report
- SOC: Soluble guanylate cyclase stimulator updates RSS · CI watch RSS
- Actelion portfolio CI